LT3442980T - Heterocikliniai junginiai, kaip ret kinazės inhibitoriai - Google Patents
Heterocikliniai junginiai, kaip ret kinazės inhibitoriaiInfo
- Publication number
- LT3442980T LT3442980T LTEPPCT/GB2017/051076T LTGB2017051076T LT3442980T LT 3442980 T LT3442980 T LT 3442980T LT GB2017051076 T LTGB2017051076 T LT GB2017051076T LT 3442980 T LT3442980 T LT 3442980T
- Authority
- LT
- Lithuania
- Prior art keywords
- rare
- kinase inhibitors
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606631 | 2016-04-15 | ||
| GB201619277 | 2016-11-14 | ||
| PCT/GB2017/051076 WO2017178844A1 (en) | 2016-04-15 | 2017-04-18 | Heterocyclic compounds as ret kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3442980T true LT3442980T (lt) | 2021-09-27 |
Family
ID=58633035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/GB2017/051076T LT3442980T (lt) | 2016-04-15 | 2017-04-18 | Heterocikliniai junginiai, kaip ret kinazės inhibitoriai |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10954241B2 (OSRAM) |
| EP (2) | EP3442980B1 (OSRAM) |
| JP (3) | JP6943876B2 (OSRAM) |
| KR (3) | KR102706837B1 (OSRAM) |
| CN (2) | CN115650985B (OSRAM) |
| AU (3) | AU2017250448C1 (OSRAM) |
| BR (2) | BR112018071097B1 (OSRAM) |
| CA (1) | CA3020778A1 (OSRAM) |
| CY (1) | CY1124478T1 (OSRAM) |
| DK (1) | DK3442980T3 (OSRAM) |
| ES (1) | ES2886587T3 (OSRAM) |
| HR (1) | HRP20211362T1 (OSRAM) |
| HU (1) | HUE056135T2 (OSRAM) |
| IL (3) | IL289793B2 (OSRAM) |
| LT (1) | LT3442980T (OSRAM) |
| MX (2) | MX387394B (OSRAM) |
| PL (1) | PL3442980T3 (OSRAM) |
| PT (1) | PT3442980T (OSRAM) |
| RS (1) | RS62322B1 (OSRAM) |
| RU (1) | RU2742115C2 (OSRAM) |
| SG (2) | SG10201911665UA (OSRAM) |
| SI (1) | SI3442980T1 (OSRAM) |
| SM (1) | SMT202100538T1 (OSRAM) |
| WO (1) | WO2017178844A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE044025T2 (hu) | 2010-05-20 | 2019-09-30 | Array Biopharma Inc | Makrociklusos vegyületek mint TRK-kináz inhibitorok |
| PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| CN115650985B (zh) | 2016-04-15 | 2024-08-02 | 癌症研究科技有限公司 | 作为ret激酶抑制剂的杂环化合物 |
| WO2017178845A1 (en) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| FI3773589T3 (fi) | 2018-04-03 | 2024-02-01 | Blueprint Medicines Corp | Ret-estäjä käytettäväksi ret-muunnoksen sisältävän syövän hoidossa |
| US11873303B2 (en) * | 2018-04-05 | 2024-01-16 | Merck Patent Gmbh | Substituted pyrazoles as type II IRAK inhibitors |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| JP7291243B2 (ja) * | 2019-04-03 | 2023-06-14 | 広州白雲山医薬集団股分有限公司白雲山制薬総廠 | Ｒｅｔ阻害剤としてのピラゾロピリジン系化合物及びその使用 |
| WO2021023209A1 (zh) * | 2019-08-05 | 2021-02-11 | 北京志健金瑞生物医药科技有限公司 | 含氮多环稠环类化合物，其药物组合物、制备方法和用途 |
| WO2021164742A1 (zh) * | 2020-02-20 | 2021-08-26 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| IL297963A (en) * | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Antagonists of the adenosine a2a receptor |
| US12448366B2 (en) | 2020-05-29 | 2025-10-21 | Rigel Pharmaceuticals, Inc. | Solid forms of pralsetinib |
| CN113214294A (zh) * | 2020-06-10 | 2021-08-06 | 深圳铂立健医药有限公司 | 三环化合物、药物组合物及其应用 |
| US11767321B2 (en) | 2020-10-05 | 2023-09-26 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
| EP4267559A1 (en) * | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Substituted indole compounds |
| TWI887510B (zh) * | 2020-12-22 | 2025-06-21 | 美商基利科學股份有限公司 | 6-取代之吲哚化合物 |
| TWI861488B (zh) | 2021-04-16 | 2024-11-11 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| CA3230800A1 (en) | 2021-09-10 | 2023-03-16 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| JP2024539641A (ja) | 2021-10-15 | 2024-10-29 | ステムライン セラピューティクス，インコーポレーテッド | 癌の治療に使用するための変異ｒｅｔキナーゼの阻害剤 |
| KR20250129803A (ko) * | 2023-01-09 | 2025-08-29 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Pparg 조정제 |
| EP4644386A1 (en) * | 2023-08-09 | 2025-11-05 | Daewoong Pharmaceutical Co., Ltd. | Novel compound, and pharmaceutical composition for prevention or treatment of cancer or tumors comprising same |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP1140938B1 (en) * | 1999-01-11 | 2003-08-27 | Princeton University | High affinity inhibitors for target validation and uses thereof |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
| EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| KR20080078668A (ko) | 2005-11-17 | 2008-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 융합된 바이사이클릭 ｍＴＯＲ 억제자 |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| CA2635231C (en) | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| JP2010532756A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP2252293B1 (en) * | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| US9096611B2 (en) * | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| EP3444242A3 (en) | 2009-11-05 | 2019-03-20 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
| EP2528919B1 (en) | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012006619A2 (en) | 2010-07-09 | 2012-01-12 | Northeastern University | ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS |
| EP2678018A4 (en) | 2011-02-23 | 2015-09-30 | Intellikine Llc | COMBINATION OF CHINESE HEMMER AND USES THEREOF |
| EP2705181B1 (en) | 2011-05-04 | 2016-12-21 | Intellikine, LLC | Combination pharmaceutical compositions and uses thereof |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| MX370814B (es) * | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| CA2854926A1 (en) | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| GB201217285D0 (en) | 2012-09-27 | 2012-11-14 | Univ Central Lancashire | Indole derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| CA2907726A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase |
| EP3057970A1 (en) | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| CA2922044A1 (en) | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
| GB201321146D0 (en) * | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| AU2015345054B2 (en) | 2014-11-14 | 2020-03-05 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| CA2974702C (en) | 2015-01-26 | 2023-10-10 | University Of Washington | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases |
| WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| KR20180109842A (ko) * | 2015-09-16 | 2018-10-08 | 록쏘 온콜로지, 인코포레이티드 | 화합물 |
| US20190077856A1 (en) | 2016-03-15 | 2019-03-14 | Memorial Sloan Kettering Cancer Center | Method of treating diseases using kinase modulators |
| WO2017178845A1 (en) * | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| CN115650985B (zh) * | 2016-04-15 | 2024-08-02 | 癌症研究科技有限公司 | 作为ret激酶抑制剂的杂环化合物 |
-
2017
- 2017-04-18 CN CN202211269931.2A patent/CN115650985B/zh active Active
- 2017-04-18 BR BR112018071097-0A patent/BR112018071097B1/pt active IP Right Grant
- 2017-04-18 IL IL289793A patent/IL289793B2/en unknown
- 2017-04-18 HU HUE17719687A patent/HUE056135T2/hu unknown
- 2017-04-18 SG SG10201911665UA patent/SG10201911665UA/en unknown
- 2017-04-18 KR KR1020227013172A patent/KR102706837B1/ko active Active
- 2017-04-18 DK DK17719687.0T patent/DK3442980T3/da active
- 2017-04-18 AU AU2017250448A patent/AU2017250448C1/en active Active
- 2017-04-18 CA CA3020778A patent/CA3020778A1/en active Pending
- 2017-04-18 MX MX2018012609A patent/MX387394B/es unknown
- 2017-04-18 ES ES17719687T patent/ES2886587T3/es active Active
- 2017-04-18 SG SG11201808878UA patent/SG11201808878UA/en unknown
- 2017-04-18 KR KR1020187032842A patent/KR102390578B1/ko active Active
- 2017-04-18 BR BR122023026297-2A patent/BR122023026297A2/pt not_active Application Discontinuation
- 2017-04-18 EP EP17719687.0A patent/EP3442980B1/en active Active
- 2017-04-18 SM SM20210538T patent/SMT202100538T1/it unknown
- 2017-04-18 PL PL17719687T patent/PL3442980T3/pl unknown
- 2017-04-18 RS RS20211115A patent/RS62322B1/sr unknown
- 2017-04-18 SI SI201730892T patent/SI3442980T1/sl unknown
- 2017-04-18 IL IL297192A patent/IL297192A/en unknown
- 2017-04-18 PT PT177196870T patent/PT3442980T/pt unknown
- 2017-04-18 HR HRP20211362TT patent/HRP20211362T1/hr unknown
- 2017-04-18 CN CN201780031509.4A patent/CN109195972B/zh active Active
- 2017-04-18 RU RU2018138471A patent/RU2742115C2/ru active
- 2017-04-18 JP JP2018554114A patent/JP6943876B2/ja active Active
- 2017-04-18 LT LTEPPCT/GB2017/051076T patent/LT3442980T/lt unknown
- 2017-04-18 WO PCT/GB2017/051076 patent/WO2017178844A1/en not_active Ceased
- 2017-04-18 US US16/093,854 patent/US10954241B2/en active Active
- 2017-04-18 EP EP21172597.3A patent/EP3960180A1/en active Pending
- 2017-04-18 KR KR1020247030356A patent/KR20240142568A/ko not_active Withdrawn
-
2018
- 2018-10-07 IL IL262185A patent/IL262185B/en unknown
- 2018-10-15 MX MX2021013110A patent/MX2021013110A/es unknown
-
2020
- 2020-08-18 AU AU2020220079A patent/AU2020220079B2/en active Active
-
2021
- 2021-02-02 US US17/165,151 patent/US11548896B2/en active Active
- 2021-09-06 CY CY20211100784T patent/CY1124478T1/el unknown
- 2021-09-07 JP JP2021145468A patent/JP2021193108A/ja active Pending
-
2022
- 2022-06-06 AU AU2022203916A patent/AU2022203916A1/en not_active Abandoned
- 2022-11-22 US US17/992,049 patent/US20230339954A1/en not_active Abandoned
-
2023
- 2023-08-10 JP JP2023131211A patent/JP2023159230A/ja active Pending
-
2024
- 2024-12-03 US US18/967,321 patent/US20250236624A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289793A (en) | Heterocyclic compounds as ret kinase inhibitors | |
| CY2024003I2 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| LT3322706T (lt) | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai | |
| LT3523301T (lt) | Pakeistieji pirazolo[1,5-a]piridino junginiai kaip ret kinazės slopikliai | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| LT3442535T (lt) | Heterocikliniai junginiai kaip ret kinazės inhibitoriai | |
| LT3609898T (lt) | Junginiai, naudingi kaip ret inhibitoriai | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| LT3461821T (lt) | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai | |
| LT3377488T (lt) | Heterocikliniai junginiai, kaip imunomoduliatoriai | |
| HUE042390T2 (hu) | Heteroaril vegyületek kinázgátlásra | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| LT3347360T (lt) | Junginiai, naudingi ror-gama-t slopinimui | |
| AU2024203236A1 (en) | Heterocyclic compounds as RET kinase inhibitors | |
| HK1260208A1 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors |